Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies

被引:46
作者
Cozzolino, Alessia [1 ]
Feola, Tiziana [1 ]
Simonelli, Ilaria [2 ]
Puliani, Giulia [1 ]
Pozza, Carlotta [1 ]
Giannetta, Elisa [1 ]
Gianfrilli, Daniele [1 ]
Pasqualetti, Patrizio [2 ]
Lenzi, Andrea [1 ]
Isidori, Andrea M. [1 ]
机构
[1] Sapienza Univ Rome, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy
[2] Fatebenefratelli Hosp, AFaR, Med Stat & Informat Technol, I-00153 Rome, Italy
关键词
LONG-ACTING OCTREOTIDE; CARDIOVASCULAR RISK-FACTORS; LANREOTIDE-AUTOGEL THERAPY; SLOW-RELEASE-LANREOTIDE; BETA-CELL FUNCTION; INSULIN-RESISTANCE; JAPANESE PATIENTS; FOLLOW-UP; EFFICACY; TERM;
D O I
10.1210/jc.2017-02566
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Somatostatin analogs (SSAs) effectively control growth hormone secretion in first-and second-line treatment of acromegaly. Their effect on glucose metabolism is still debated. Objective: To address the following questions: (1) Do SSAs affect fasting plasma glucose (FPG), fasting plasma insulin, glycosylated hemoglobin (HbA1c), glucose load (glucose levels after 2-hour oral glucose tolerance test), homeostatic model assessment of insulin resistance (HOMA-I), homeostatic model assessment of pancreatic beta-cell function (HOMA-beta), triglycerides, weight, or body mass index? (2) Do lanreotide and octreotide affect metabolism differently? (3) Does their effect depend on disease control? Design: We performed a meta-analysis of prospective interventional trials treating acromegaly with SSAs. Inclusion criteria: all studies reporting glycometabolic outcomes before and after SSAs with a minimum 6-month follow-up. Results: The inclusion criteria were met by 47 studies treating 1297 subjects (631 females). SSA treatment effectively lowered fasting plasma insulin [effect size (ES), -6.67 mU/L; 95% confidence interval (CI), -8.38 to -4.95 mU/L; P < 0.001], HOMA-I (ES, -1.57; CI, -2.42 to -0.72; P < 0.001), HOMA-b (ES, -47.45; CI, -73.15 to -21.76; P < 0.001), and triglycerides (ES, -0.37 mmol/L; CI, -0.47 to -0.27 mmol/L; P < 0.001). SSAs worsened glucose levels after a 2-hour oral glucose tolerance test (ES, 0.59 mmol/L; CI, 0.05 to 1.13 mmol/L; P = 0.032), but not FPG. A mild but significant increase in HbA1c (ES, 0.12%; CI, 0.00% to 0.25%; P = 0.044) was found in subjects treated with octreotide. Conclusions: SSA treatment in acromegaly patients, while improving disease control, reduces insulin levels, increases after-load glucose, and, ultimately, increases HbA1c levels without affecting FPG. The findings suggest that clinicians treating acromegaly with SSAs should consider targeting postprandial glucose.
引用
收藏
页码:2089 / 2099
页数:11
相关论文
共 69 条
  • [1] Optimalization and cost management of lanreotide-Autogel therapy in acromegaly
    Abrams, Pascale
    Alexopoulou, Orsalia
    Abs, Roger
    Maiter, Dominique
    Verhelst, Johan
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2007, 157 (05) : 571 - 577
  • [2] Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotide LAR
    Alexopoulou, O
    Abrams, P
    Verhelst, J
    Poppe, K
    Velkeniers, B
    Abs, R
    Maiter, D
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 151 (03) : 317 - 324
  • [3] The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly
    AlMaskari, M
    Gebbie, J
    KendallTaylor, P
    [J]. CLINICAL ENDOCRINOLOGY, 1996, 45 (04) : 415 - 421
  • [4] Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly
    Ambrosio, MR
    Franceschetti, P
    Bondanelli, M
    Doga, M
    Maffei, P
    Baldelli, R
    Tamburrano, G
    Sicolo, N
    Giustina, A
    degli Uberti, E
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (03): : 387 - 393
  • [5] A 12-month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly
    Andries, Magdalene
    Glintborg, Dorte
    Kvistborg, Annette
    Hagen, Claus
    Andersen, Marianne
    [J]. CLINICAL ENDOCRINOLOGY, 2008, 68 (03) : 473 - 480
  • [6] Attanasio Roberto, 2008, Endocr Pract, V14, P846
  • [7] Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly
    Auriemma, Renata S.
    Grasso, Ludovica F. S.
    Galdiero, Mariano
    Galderisi, Maurizio
    Pivonello, Claudia
    Simeoli, Chiara
    De Martino, Maria Cristina
    Ferrigno, Rosario
    Negri, Mariarosaria
    de Angelis, Cristina
    Pivonello, Rosario
    Colao, Annamaria
    [J]. ENDOCRINE, 2017, 55 (03) : 872 - 884
  • [8] Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly
    Ayuk, J
    Stewart, SE
    Stewart, PM
    Sheppard, MC
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (09) : 4142 - 4146
  • [9] Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy
    Baldelli, R
    Durante, C
    D'Amico, E
    Diacono, F
    Tamburrano, G
    Casanueva, FF
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2003, 26 (12) : 1219 - 1224
  • [10] Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment
    Baldelli, Roberto
    Battista, Claudia
    Leonetti, Frida
    Ghiggi, Maria-Rosaria
    Ribaudo, Maria-Cristina
    Paoloni, Antonella
    D'Amico, Eugenio
    Ferretti, Elisabetta
    Baratta, Roberto
    Liuzzi, Antonio
    Trischitta, Vincenzo
    Tamburrano, Guido
    [J]. CLINICAL ENDOCRINOLOGY, 2003, 59 (04) : 492 - 499